Recruiting NCT03966170
Citicoline as Neuroprotector in Preterm
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Citicoline, Placebo oral tablet.
- Who it may be relevant to
- Registry conditions: Pre-Term. Basic parameters: up to 1 months · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial
Overview
Citicoline as neuroprotector in preterm
Detailed description
Efficacy of Citicoline as neuroprotector in preterm; A randomized controlled trial.
Interventions
- Drug Citicoline
Citicoline as neuroprotector - Drug Placebo oral tablet
placebo drug
Primary outcome measures
- Number of children with affection of the brain [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Preterm on CPAP or ventilator
Exclusion criteria
- Multiple congenital anomalies
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Sherief Abd-Elsalam — Tanta
Identifiers
NCT: NCT03966170 · Citicoline